SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 674.95+3.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2976)6/3/2020 12:53:27 PM
From: CuttingEdge Bio1 Recommendation

Recommended By
DewDiligence_on_SI

   of 3557
 
There are too many warts on the existing developing hemo geneTx treatments, that the theory behind this is too good to pass up. No AAV involved at all, which means redose at will. And they also don't have the crispr components sitting in the cell forever waiting for DNA breaks to do nonspecific cuts or integrations (like other crispr players would) as it's designed as a transient expression. In my opinion, IN THEORY, this is a big solution and if it gets into clinic soon and shows something big soon in patient results, it could put the idea in people's heads to wait for it! Could throw a wrench for some of the upcoming launches that are ahead of them. They would have to move as quickly as possible to mitigate the real risk of market being saturated by one-time treatments and temporarily curing the patients out of the market. Then again, if those fade away like Valrox, the patients "removed" from market, may return to market in a handful of years.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News